

Yvette Bernal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6589156/publications.pdf>

Version: 2024-02-01

10
papers

6,078
citations

1162367

8
h-index

1372195

10
g-index

10
all docs

10
docs citations

10
times ranked

6806
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. Science Translational Medicine, 2014, 6, 224ra25.	5.8	2,069
2	CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. Science Translational Medicine, 2013, 5, 177ra38.	5.8	1,748
3	Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood, 2011, 118, 4817-4828.	0.6	1,135
4	Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Cancer Discovery, 2018, 8, 958-971.	7.7	594
5	Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial. Molecular Therapy, 2010, 18, 666-668.	3.7	358
6	Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. JCI Insight, 2019, 4, .	2.3	71
7	CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. Blood, 2019, 134, 626-635.	0.6	59
8	Implications of Minimal Residual Disease Negative Complete Remission (MRD-CR) and Allogeneic Stem Cell Transplant on Safety and Clinical Outcome of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed, Refractory B-Cell ALL. Blood, 2015, 126, 682-682.	0.6	37
9	Impact of the Conditioning Chemotherapy On Outcomes in Adoptive T Cell Therapy: Results From a Phase I Clinical Trial of Autologous CD19-Targeted T Cells for Patients with Relapsed CLL. Blood, 2012, 120, 1797-1797.	0.6	6
10	Phase II Trial of WT1 Analog Peptide Vaccine in Patients with Acute Myeloid Leukemia (AML) in Complete Remission (CR). Blood, 2012, 120, 3624-3624.	0.6	1